4 news items
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
NUVL
29 May 24
is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
NUVL
16 May 24
cell lung cancer (NSCLC) and is currently being investigated in the ALKOVE-1 clinical trial
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
NUVL
9 May 24
with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
NUVL
8 Apr 24
and in vivo analyses of NVL-330 with currently approved and investigational HER2-targeting agents, NVL-330 demonstrated a differentiated
- Prev
- 1
- Next